Skip to main content

Mark Eccleston

Oct 26, 2026

20:34
How are you, Mark?
20:35
Morning, I'm great.
20:36
Thanks, guys.
20:36
Nice to see you all.
20:38
Could you give us a summary of your company, please? Sure.
20:41
So Valorix is a preclinical early stage drug developer.
20:45
We identify interesting assets typically from tech transfer offices, universities, sometimes small biotech.

10 MINS LATER

30:50
How much of it do you expect to retain? How much are you going to give away?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.